We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > IRAK4

News List

Emmaus Life Sciences Acquires Key Intellectual Property Rights to Novel IRAK4 Inhibitor From Kainos Medicine prnasia
October 13, 2021
Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced the signing of an agreement with Kainos Medicine, Inc.
Kymera Therapeutics, Sanofi collaborate to advance novel protein degrader therapies to patients pharmaceutical-business-review
July 15, 2020
Kymera Therapeutics announced the company has entered into a multi-program strategic collaboration with Sanofi to develop and commercialise first-in-class protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases.
Sanofi partners with Kymera in $2bn protein degrader therapies deal pharmaceutical-technology
July 10, 2020
Sanofi has formed a multi-programme collaboration with biotechnology firm Kymera Therapeutics to develop and commercialise protein degrader therapies that target IRAK4 in immune-inflammatory diseases.
Kymera, Sanofi Enter Multi-program Strategic Alliance contractpharma
July 10, 2020
To develop and commercialize first-in-class protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases.